Collectively, our data substantiate that targeting either DCAF7 or USP2 induces ferroptosis to potentiate sorafenib sensitivity through ferroptosis in vitro and in vivo and highlight the combination of sorafenib and USP2 inhibitors as a promising strategy for improving clinical outcomes in HCC patients. Here, DCAF7 is linked to hepatocellular carcinoma.